arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

OS Therapies Inc

OSTX

$1.58 ▼ -0.05 (-3.35%) at close

14 Visible periods

20 Metrics

Absolute Benchmarks

Price Chart

Health

Poor

Neutral Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, OS Therapies Inc shows solid but mixed fundamentals, with Return on Invested Capital holding up well. Watch FCF / Net Income against typical quality thresholds. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap —

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC 74.2% ↘

FCF / Share None

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

14-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-10.40M

↓ -168.2% —

FCF / Share Free cash flow per share

$-0.16

↓ -5.5% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

Return on Invested CapitalReturn on Invested Capital of 372.0% is excellent on an absolute basis (target > 10%)

warning

Bearish Risks

FCF / Net IncomeFCF / Net Income of 0.50x is weak on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Mar 7, 2024 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
EPS Growth YoY (%)	-50.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	35.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-16.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	26.9% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	—	24.7% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	52.6% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	44.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	-168.2% Weak ↑ Weak Improving Year-over-year change in net income	-350.0% Weak ↓ Weak Declining Year-over-year change in net income	-165.7% Weak ↓ Weak Declining Year-over-year change in net income	-165.7% Weak ↓ Weak Declining Year-over-year change in net income	-165.7% Weak ↓ Weak Declining Year-over-year change in net income	-104.2% Weak ↓ Weak Declining Year-over-year change in net income	21.0% Good → Good Stable Year-over-year change in net income	21.0% Good Good Year-over-year change in net income	21.0% Good Good Year-over-year change in net income	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Mar 7, 2024 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
FCF / Net Income (x)	0.44x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.28x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.21x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.61x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	0.44x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.59x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.47x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.45x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.23x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Mar 7, 2024 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	74.2% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	155.4% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-149.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-77.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	94.3% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	71.7% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	272.3% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	2.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	2.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	3.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	2.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	5.6% Caution Caution Return earned on debt + equity capital invested Optimal: > 10%	4.4% Caution Caution Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-139.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-175.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-76.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-46.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-117.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-53.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-123.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-58.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-60.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-145.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	96.1% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+540%)	220.8% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1372%)	-106.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-811%)	-78.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-623%)	92.6% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+517%)	91.6% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+510%)	206.3% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1276%)	5.4% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-64%)	5.7% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-62%)	6.1% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-59%)	8.2% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-45%)	8.7% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-42%)	9.9% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-34%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Mar 7, 2024 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Debt to Equity (x)	—	—	—	—	—	—	—	-0.01x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-102%)	-0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-101%)	-0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-101%)	—	—	—	—
Interest Coverage (x)	—	—	—	—	—	—	—	—	-0.76x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	-1.31x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	—	—	—	—	—	—	—	$250.00K	$100.00K	$100.00K	—	—	—	—
Debt / EBITDA (x)	—	—	—	—	—	—	—	-0.32x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.16x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.09x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Mar 7, 2024 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Basic EPS, GAAP (USD)	$-0.27	$-0.41	$-0.21	$-0.19	$-0.18	$-0.64	$-0.18	$-0.26	—	$-0.85	$-0.38	$-0.47	—	—
Free Cash Flow per Share (USD)	—	—	—	—	—	—	—	—	—	—	$-0.16	$-0.16	—	—
Book Value per Share (USD)	$-0.28	$-0.16	$0.11	$0.17	$-0.20	$-0.16	$-0.03	$-4.52	$-2.13	$-4.50	$-4.22	$-3.98	—	—
Tangible Book Value per Share (USD)	$-0.28	$-0.16	$0.11	$0.17	$-0.20	$-0.16	$-0.03	$-4.52	$-2.13	$-4.50	$-4.22	$-3.98	—	—
Basic Weighted Avg Shares (shares)	—	—	—	—	—	—	15.90M	5.99M	—	—	5.34M	5.34M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Mar 7, 2024 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$-16.04M	$-11.43M	$-1.82M	$95.94K	$559.09K	$906.22K	$-613.79K	$-26.97M	$-25.41M	$-23.92M	—	—	—	—
Total Equity (USD)	$-10.82M	$-6.10M	$3.64M	$4.94M	$-4.19M	$-3.27M	$-707.13K	$-27.06M	$-25.51M	$-24.02M	$-22.52M	$-21.27M	$-18.74M	$-17.56M

📋 What is driving earnings? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Mar 7, 2024 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Depreciation Expense (USD)	—	—	—	—	$695.00	—	$0.00	$695.00	$695.00	$0.00	$3.31K	$805.00	$100.00	—
Net Income, GAAP (USD)	$-10.40M	$-13.46M	$-3.88M	$-3.88M	$-3.88M	$-2.99M	$-1.46M	$-1.46M	$-1.46M	$-1.46M	$-1.85M	$-1.85M	$-1.85M	—
Operating Cash Flow (USD)	$-4.56M	$-3.73M	$-4.71M	$-2.36M	$-3.44M	$-2.37M	—	—	$-641.73K	$-871.16K	$-876.57K	$-831.05K	$-428.19K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 14 quarters

OS Therapies Inc

Analytical Summary

14-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare OSTX with peers